Amira completes Ph I AM103 assessment

California, USA-based drugmaker Amira Pharmaceuticals has completed a Phase I trial of AM103, its oral anti-inflammatory product candidate. The drug is designed to inhibit 5-lipoxygenase-activating protein, which is part of the inflammatory leukotriene pathway.

Amira explained that both AM103, and a second developmental agent AM803, have demonstrated considerable potential as treatments for asthma and cardiovascular disease. The compounds have been shown to prevent the synthesis of the leukotriene molecules known to trigger the inflammation associated with each condition.

AM103 trial demonstrates safety